23 mayo 2017

Yondelis combinado con Avelumab (Bavencio) ( Fase I-II ) . First Extensive Immune Profiling of Sarcomas Shows Possible Susceptibility to Immunotherapy .

By The ASCO Post // Posted :  5 / 22 / 2017 .

... Ongoing Study

Dr. Pollack is conducting ongoing clinical trials combining chemotherapies and checkpoint inhibitors in patients with metastatic or unresectable sarcomas—one focusing on pembrolizumab (Keytruda) and doxorubicin hydrochloride combination treatment and the other studying the combination of avelumab (Bavencio) and trabectedin (Yondelis).

Ultimately, he hopes to expand treatment options for patients with advanced sarcoma, who have an estimated survival of 12 to 18 months.

The Sarcoma Alliance for Research through Collaboration, the Sarcoma Foundation for America, and the Gilman Sarcoma Foundation funded the research.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.